Goldman Sachs Group Inc. Lowers Holdings in Atossa Genetics Inc. $ATOS

Goldman Sachs Group Inc. cut its position in Atossa Genetics Inc. (NASDAQ:ATOS) by 45.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,927 shares of the company’s stock after selling 156,931 shares during the quarter. Goldman Sachs Group Inc. owned about 0.15% of Atossa Genetics worth $126,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its position in shares of Atossa Genetics by 40.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company’s stock valued at $284,000 after buying an additional 120,934 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Atossa Genetics during the 1st quarter valued at $115,000. Bank of America Corp DE raised its position in shares of Atossa Genetics by 51.3% during the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock valued at $105,000 after buying an additional 37,809 shares in the last quarter. Two Sigma Advisers LP raised its position in shares of Atossa Genetics by 214.1% during the 4th quarter. Two Sigma Advisers LP now owns 42,400 shares of the company’s stock valued at $40,000 after buying an additional 28,900 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Atossa Genetics during the 4th quarter valued at $28,000. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Genetics Price Performance

NASDAQ:ATOS opened at $0.87 on Tuesday. The firm has a market capitalization of $112.73 million, a P/E ratio of -3.79 and a beta of 1.10. Atossa Genetics Inc. has a one year low of $0.55 and a one year high of $1.66. The company’s 50-day simple moving average is $0.81 and its 200 day simple moving average is $0.80.

Atossa Genetics (NASDAQ:ATOS) last issued its earnings results on Tuesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01). On average, equities research analysts expect that Atossa Genetics Inc. will post -0.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Ascendiant Capital Markets raised their price objective on shares of Atossa Genetics from $7.50 to $7.75 and gave the company a “buy” rating in a research report on Monday, September 22nd. Craig Hallum upgraded shares of Atossa Genetics to a “strong-buy” rating and set a $4.00 price objective on the stock in a research report on Thursday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $6.25.

Atossa Genetics Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.